Targeted Therapy-induced Facial Skin Toxicities

Impact on Quality of Life in Cancer Patients

Research output: Contribution to journalArticle

Abstract

Objective: Targeted therapy-induced facial skin toxicities may reduce overall quality of life (QoL) in cancer patients. We investigated whether facial skin toxicities affect QoL and attempted to identify factors related to QoL in patients with advanced/recurrent cancer. Methods: We performed a cross-sectional study in 34 outpatients with advanced/recurrent cancer showing targeted therapy-induced facial skin toxicities in Japan between November 2016 and February 2017. For measurement, we used the Kessler Psychological Distress Scale (K6), Mental Adjustment to Cancer (MAC) Scale, and Dermatology Life Quality Index (DLQI). Data were analyzed using Spearman's rank correlation coefficient. Results: Mean DLQI score in 34 patients was 4.59 (standard deviation ± 4.70), which was interpreted as a small effect on a patient's life. Acneiform rash was the most common skin condition noted, followed by xerosis, pruritus, and erythema. Analysis of DLQI scores revealed that symptoms and feelings was the domain most commonly affected among different domains constituting the DLQI. MAC analysis revealed that the fighting spirit score was the highest among MAC scales. We found that age, K6, and fatalism construct in MAC were significantly correlated with total DLQI scores (age: Spearman's ρ= -0.48, P = 0.004; K6: ρ= 0.58, P < 0.001; fatalism; ρ= -0.39, P = 0.025). Conclusions: This is the first study investigating targeted therapy-induced facial skin toxicities in cancer patients. Our results suggest potential negative effects of facial skin toxicities on overall QoL in patients with advanced/recurrent cancer in middle and early old age.

Original languageEnglish
Pages (from-to)172-177
Number of pages6
JournalAsia-Pacific Journal of Oncology Nursing
Volume5
Issue number2
DOIs
Publication statusPublished - 2018 Apr 1

Fingerprint

Quality of Life
Skin
Social Adjustment
Dermatology
Neoplasms
Therapeutics
Erythema
Pruritus
Nonparametric Statistics
Exanthema
Japan
Emotions
Outpatients
Cross-Sectional Studies
Psychology

Keywords

  • Advanced/recurrent cancer patient
  • facial skin toxicities
  • quality of life
  • targeted therapy

ASJC Scopus subject areas

  • Oncology
  • Oncology(nursing)

Cite this

@article{3c4fb96c83fd4e928df8113eb671a130,
title = "Targeted Therapy-induced Facial Skin Toxicities: Impact on Quality of Life in Cancer Patients",
abstract = "Objective: Targeted therapy-induced facial skin toxicities may reduce overall quality of life (QoL) in cancer patients. We investigated whether facial skin toxicities affect QoL and attempted to identify factors related to QoL in patients with advanced/recurrent cancer. Methods: We performed a cross-sectional study in 34 outpatients with advanced/recurrent cancer showing targeted therapy-induced facial skin toxicities in Japan between November 2016 and February 2017. For measurement, we used the Kessler Psychological Distress Scale (K6), Mental Adjustment to Cancer (MAC) Scale, and Dermatology Life Quality Index (DLQI). Data were analyzed using Spearman's rank correlation coefficient. Results: Mean DLQI score in 34 patients was 4.59 (standard deviation ± 4.70), which was interpreted as a small effect on a patient's life. Acneiform rash was the most common skin condition noted, followed by xerosis, pruritus, and erythema. Analysis of DLQI scores revealed that symptoms and feelings was the domain most commonly affected among different domains constituting the DLQI. MAC analysis revealed that the fighting spirit score was the highest among MAC scales. We found that age, K6, and fatalism construct in MAC were significantly correlated with total DLQI scores (age: Spearman's ρ= -0.48, P = 0.004; K6: ρ= 0.58, P < 0.001; fatalism; ρ= -0.39, P = 0.025). Conclusions: This is the first study investigating targeted therapy-induced facial skin toxicities in cancer patients. Our results suggest potential negative effects of facial skin toxicities on overall QoL in patients with advanced/recurrent cancer in middle and early old age.",
keywords = "Advanced/recurrent cancer patient, facial skin toxicities, quality of life, targeted therapy",
author = "Kaori Yagasaki and Hiroko Komatsu and Kenzo Soejima and Katsuhiko Naoki and Ichiro Kawada and Hiroyuki Yasuda and Yasuo Hamamoto",
year = "2018",
month = "4",
day = "1",
doi = "10.4103/apjon.apjon_74_17",
language = "English",
volume = "5",
pages = "172--177",
journal = "Asia-Pacific Journal of Oncology Nursing",
issn = "2347-5625",
publisher = "Wolters Kluwer Medknow Publications",
number = "2",

}

TY - JOUR

T1 - Targeted Therapy-induced Facial Skin Toxicities

T2 - Impact on Quality of Life in Cancer Patients

AU - Yagasaki, Kaori

AU - Komatsu, Hiroko

AU - Soejima, Kenzo

AU - Naoki, Katsuhiko

AU - Kawada, Ichiro

AU - Yasuda, Hiroyuki

AU - Hamamoto, Yasuo

PY - 2018/4/1

Y1 - 2018/4/1

N2 - Objective: Targeted therapy-induced facial skin toxicities may reduce overall quality of life (QoL) in cancer patients. We investigated whether facial skin toxicities affect QoL and attempted to identify factors related to QoL in patients with advanced/recurrent cancer. Methods: We performed a cross-sectional study in 34 outpatients with advanced/recurrent cancer showing targeted therapy-induced facial skin toxicities in Japan between November 2016 and February 2017. For measurement, we used the Kessler Psychological Distress Scale (K6), Mental Adjustment to Cancer (MAC) Scale, and Dermatology Life Quality Index (DLQI). Data were analyzed using Spearman's rank correlation coefficient. Results: Mean DLQI score in 34 patients was 4.59 (standard deviation ± 4.70), which was interpreted as a small effect on a patient's life. Acneiform rash was the most common skin condition noted, followed by xerosis, pruritus, and erythema. Analysis of DLQI scores revealed that symptoms and feelings was the domain most commonly affected among different domains constituting the DLQI. MAC analysis revealed that the fighting spirit score was the highest among MAC scales. We found that age, K6, and fatalism construct in MAC were significantly correlated with total DLQI scores (age: Spearman's ρ= -0.48, P = 0.004; K6: ρ= 0.58, P < 0.001; fatalism; ρ= -0.39, P = 0.025). Conclusions: This is the first study investigating targeted therapy-induced facial skin toxicities in cancer patients. Our results suggest potential negative effects of facial skin toxicities on overall QoL in patients with advanced/recurrent cancer in middle and early old age.

AB - Objective: Targeted therapy-induced facial skin toxicities may reduce overall quality of life (QoL) in cancer patients. We investigated whether facial skin toxicities affect QoL and attempted to identify factors related to QoL in patients with advanced/recurrent cancer. Methods: We performed a cross-sectional study in 34 outpatients with advanced/recurrent cancer showing targeted therapy-induced facial skin toxicities in Japan between November 2016 and February 2017. For measurement, we used the Kessler Psychological Distress Scale (K6), Mental Adjustment to Cancer (MAC) Scale, and Dermatology Life Quality Index (DLQI). Data were analyzed using Spearman's rank correlation coefficient. Results: Mean DLQI score in 34 patients was 4.59 (standard deviation ± 4.70), which was interpreted as a small effect on a patient's life. Acneiform rash was the most common skin condition noted, followed by xerosis, pruritus, and erythema. Analysis of DLQI scores revealed that symptoms and feelings was the domain most commonly affected among different domains constituting the DLQI. MAC analysis revealed that the fighting spirit score was the highest among MAC scales. We found that age, K6, and fatalism construct in MAC were significantly correlated with total DLQI scores (age: Spearman's ρ= -0.48, P = 0.004; K6: ρ= 0.58, P < 0.001; fatalism; ρ= -0.39, P = 0.025). Conclusions: This is the first study investigating targeted therapy-induced facial skin toxicities in cancer patients. Our results suggest potential negative effects of facial skin toxicities on overall QoL in patients with advanced/recurrent cancer in middle and early old age.

KW - Advanced/recurrent cancer patient

KW - facial skin toxicities

KW - quality of life

KW - targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=85056726324&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85056726324&partnerID=8YFLogxK

U2 - 10.4103/apjon.apjon_74_17

DO - 10.4103/apjon.apjon_74_17

M3 - Article

VL - 5

SP - 172

EP - 177

JO - Asia-Pacific Journal of Oncology Nursing

JF - Asia-Pacific Journal of Oncology Nursing

SN - 2347-5625

IS - 2

ER -